ESMO 2020

Showing 3 posts of 3 posts found.

merckincweb

Positive five-year Keytruda survival data revealed at ESMO in metastatic, PD-L1+ non-small cell lung cancer

September 22, 2020
Manufacturing and Production, Research and Development ESMO 2020, MSD, keytruda, pharma

MSD took the opportunity at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 to unveil new Phase 3 …

shutterstock_159488225

Piqray and Faslodex combo extends survival in HR+/HER2-, PIK3CA+ advanced breast cancer at ESMO 2020

September 21, 2020
Research and Development, Sales and Marketing Cancer, ESMO 2020, Novartis, pharma

New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of …

libtayo

Promising Phase 2 data for Sanofi and Regeneron’s PD-1 inhibitor Libtayo in locally advanced basal cell carcinoma

September 18, 2020
Medical Communications, Research and Development Cancer, ESMO 2020, Libtayo, Regeneron, Sanofi, pharma

Promising Phase 2 data has been released at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 for Sanofi …

Latest content